Didanosine (ddI) ameliorates neutropenia in patients with HIV-related non-Hodgkin's lymphoma (NHL) treated with infusional cyclophosphamide, doxorubicin, and etoposide (CDE) (Meeting abstract).

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Didanosine (ddI) ameliorates neutropenia in patients with HIV-related non-Hodgkin's lymphoma (NHL) treated with infusional cyclophosphamide, doxorubicin, and etoposide (CDE) (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 36:A1207 1995. Unique Identifier : AIDSLINE ICDB/95608984
Sparano JA; Wiernik PH; Leaf A; Henry D; Mason B; Sarta C; Hu X; Dutcher JP; Montefiore Medical Center, Bronx, NY 10467

Abstract: We reported a 62% complete response (CR) rate and 18-mo median survival for 21 patients (pts) with HIV-related NHL treated with infusional CDE (Blood 81:2810, 1993; Leukemia and Lymphoma 14:263, 1994), but observed substantial myelosuppression and decreased CD4+ lymphocytes (111/ul +/- 23 pre vs 52 +/- 12 post 2 cycles, p=0.04). Since ddi ameliorates HIV-related cytopenias (Blood 80:2969, 1992), we initiated a pilot trial to evaluate the feasibility of combining ddI (200 mg PO BID, cycles 1,2,5,6 or 3,4,5,6) with CDE. Granulocyte-colony stimulating factor (5 mg/kg/day) was given day 5- recovery. Pt characteristics: N=18; prior antiretrovirals (12); median CD4 count (117/ul); histology J (8), H (6), G (4); + marrow (7); Stage IV (16). Multiple regression analysis was performed to evaluate the effect of the following variables on leukocyte (WBC), neutrophil (ANC), and platelet (PTL) nadir: ddI use, CD4 count, + marrow, cycle number, chemo dose. ddI use was associated with a significantly higher WBC (p=0.002) and ANC nadir (p=0.015), but not post-therapy CD4. Lower baseline CD4 was associated with deeper PTL nadir (p=0.01). Marrow involvement was associated by significantly deeper WBC, ANC, and platelet nadirs, as expected. CR occurred in 7/11 (64%) evaluable pts who have completed all therapy.

Keywords: Antineoplastic Agents, Combined/*ADVERSE EFFECTS/THERAPEUTIC USE Cyclophosphamide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Didanosine/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Doxorubicin/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Etoposide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Follow-Up Studies Human Infusions, Intravenous Lymphoma, AIDS-Related/*DRUG THERAPY/IMMUNOLOGY/MORTALITY Neutropenia/*CHEMICALLY INDUCED/DRUG THERAPY/IMMUNOLOGY/MORTALITY Pilot Projects Survival Rate ABSTRACT
950830
M9580998

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .